Alexion Pharmaceuticals - Articles and news items

Vtesse appoints Jason Meyenburg as Chief Commercial Officer

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

Meyenburg joins the company from Alexion Pharmaceuticals, where he most recently served as Senior Vice President of Commercial Operations.

NICE recommends new rare inherited bone disorder drug for children

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life…

NICE calls for more research into Alexion’s sebelipase alfa

Industry news / 18 February 2016 / Victoria White

NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency…

FDA approves Alexion’s Kanuma for LAL deficiency

Industry news / 9 December 2015 / Victoria White

Kanuma (sebelipase alfa) has been approved for the treatment of patients with a diagnosis of lysosomal acid lipase deficiency (LAL-D)…

NICE says ‘no’ to asfotase alfa in draft guidance

Industry news / 3 December 2015 / Victoria White

NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia…

Pivotal Phase 3 data on Kanuma in LAL-D published

Industry news / 10 September 2015 / Victoria White

In the Phase 3 study, Kanuma met the primary endpoint of alanine aminotransferase (ALT) normalisation compared with placebo as well as six secondary endpoints…

European marketing authorisation granted for Alexion's Kanuma™ (sebelipase alfa)

European marketing authorisation granted for Alexion’s Kanuma™ (sebelipase alfa)

Industry news / 1 September 2015 / Nick Jackson

Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency…

Pharma companies rank high on Forbes’ most innovative list

Industry news / 19 August 2015 / Victoria White

Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine’s 2015 list of the “World’s Most Innovative Companies”…

Alexion receives CHMP positive opinions for Strensiq and Kanuma

Industry news / 26 June 2015 / Victoria White

Alexion has announced that the CHMP of the EMA has adopted positive opinions recommending marketing authorisation of Strensiq and Kanuma…

Alexion Pharmaceuticals acquires Synageva BioPharma

Industry news / 23 June 2015 / Victoria White

Alexion Pharmaceuticals has successfully completed its acquisition of Synageva BioPharma, strengthening Alexion’s position in devastating and rare diseases…

Alexion to acquire Synageva in $8.4 billion deal

Industry news / 7 May 2015 / Victoria White

Alexion Pharmaceuticals has announced that it is set to acquire Synageva BioPharma in a transaction valued at approximately $8.4 billion…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...